Contact Information: For more information, please contact: Stephanie Swanson 919-433-0212
Cutting Edge Information Sees Burst of Innovation From Pharma and Biotech, Studies Regulatory Atmosphere
| Source: Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwire - November 3, 2009) - The pharmaceutical and
biotechnology industries are on the verge of both a burst of innovative new
products and a change in mindset from stereotypical "pill pushers" to
breaking through to the vanguard of healthcare solution providers,
according to recent work by business research firm Cutting Edge Information
(CEI).
In addition to other recent positive developments across the life sciences
industries, yesterday's call from Eli Lilly Chief Executive Officer John
Lechleiter for the industry to "reinvent innovation"
(http://www.pharmatimes.com/WorldNews/article.aspx?id=16843&src=EWorldNews)
is another towering guidepost for all companies to continue producing new
medicines and treatments and to better communicate the benefits that the
industry brings to society.
CEI's research over the last decade has shown swings in both the industry's
approach to driving new drug development and communicating the value of
that work to the world's health. As regulatory pressure has increased
because of overall healthcare changes, the industry has clarified and
strengthened its message. While progress has been made in educating
various stakeholders, including physicians, patients and payers, much work
remains to be done.
"No other industry has to balance the massive dual challenges of public
demand for rapid innovation and sometimes 'miracle' cures with such
incredibly strict regulatory oversight," said Jason Richardson, president
of CEI. "Of course, both of those demands are understandable -- people
want to see the fruits of science, particularly when a loved one's health
is at stake, but they also want the government and industry's assurances
that these advances are not going to do more harm than good."
Across various therapeutic areas
(http://www.cuttingedgeinfo.com/reports/forecasting-market-research.php),
companies are making advances into ever more complicated science. And
every company is working to make its clinical development, medical affairs,
patient education and lifecycle management programs more productive, both
for shareholder value and for the efficiency of the overall healthcare
system (http://www.cuttingedgeinfo.com ).
"Pharmaceuticals and Biotechnology have faced an especially tough wave of
specific issues that have clouded their picture," said Adam Bianchi, chief
operating officer of CEI. "Some of that externally driven cloud has
lifted, and now companies are plotting the strategies that will really let
them clear the smoke and blaze productive paths forward to 2011, 2015, and
beyond."